Clinical Trial Update: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of R935788 for persistent or chronic immune thrombocytopenia has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• R935788

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Immune Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2019-01-11